Search
Atrasentan
go.drugbank.com/drugs/DB06199ApprovedInvestigationalAtrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalTapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. … [L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesSynonyms: 3-[(1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol, PHENOL, 3-((1R,2R)-3-(DIMETHYLAMINO)-1-ETHYL-2-METHYLPROPYL)-Eltrombopag
go.drugbank.com/drugs/DB06210ApprovedInvestigationalITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesProducts: REVOLADE® TABLETAS 25 MG, REVOLADE ® TABLETAS 50 MGDoripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … , resulting in a premature termination of the trial.
Categories: Heterocyclic Compounds, 2-RingProducts: DORVAK®, DORIPURE® 500Eflornithine
go.drugbank.com/drugs/DB06243ApprovedInvestigationalWithdrawnEflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. … [A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or interacts with ras, both very well-known oncogenes, thus increasing the interest in targeting ornithine carboxylase as a
Synonyms: (RS)-2,5-diamino-2-(difluoromethyl)pentanoic acid, 2-(difluoromethyl)ornithineDapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [A6757] Dapagliflozin has been investigated either as monotherapy or as an adjunct treatment with insulin or other oral hypoglycemic agents.
Mixtures: XIGLIF-M, PLEMTUM-MCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesElinogrel
go.drugbank.com/drugs/DB06350InvestigationalA P2Y12 inhibitor and platelet aggregation inhibitor.
Categories: Heterocyclic Compounds, 2-RingXaliproden
go.drugbank.com/drugs/DB06393InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Serotonin 5-HT1 Receptor AntagonistsBazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalIt is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. … Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals.
Categories: Heterocyclic Compounds, 2-Ring